Memorial Sloan-Kettering Cancer Center;Agenus Inc.;Ludwig Institute for Cancer Research Ltd.
发明人:
Nicholas S. WILSON,Jeremy D. WAIGHT,Gerd RITTER,David SCHAER,Daniel HIRSCHHORN-CYMERMAN,Taha MERGHOUB,Ekaterina V. BREOUS-NYSTROM,Volker SEIBERT,Takemasa TSUJI,Olivier LÉGER,Dennis J. Underwood,Marc V
申请号：
US15781043
公开号：
US20200079861A1
申请日:
2016.12.02
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
